Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study. [electronic resource]
Producer: 20190528ISSN:- 1399-0012
- Antiviral Agents -- therapeutic use
- Carbamates
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Hepacivirus -- isolation & purification
- Hepatitis C -- complications
- Humans
- Imidazoles -- therapeutic use
- Italy
- Liver Cirrhosis -- drug therapy
- Liver Transplantation -- adverse effects
- Male
- Middle Aged
- Prognosis
- Prospective Studies
- Pyrrolidines
- Recurrence
- Ribavirin -- therapeutic use
- Sofosbuvir -- therapeutic use
- Valine -- analogs & derivatives
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.